C3N-02300
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 69.44832307
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.460
- MYC_TARGETS_V1+0.380
- MYC_TARGETS_V2+0.330
- HYPOXIA+0.320
- HEDGEHOG_SIGNALING+0.300
- DNA_REPAIR+0.290
- P53_PATHWAY+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- MTORC1_SIGNALING+0.280
Top 10 suppressed
- BILE_ACID_METABOLISM-0.290
- PROTEIN_SECRETION-0.250
- INTERFERON_GAMMA_RESPONSE-0.240
- COMPLEMENT-0.200
- INTERFERON_ALPHA_RESPONSE-0.200
- ANDROGEN_RESPONSE-0.190
- COAGULATION-0.170
- KRAS_SIGNALING_UP-0.170
- IL6_JAK_STAT3_SIGNALING-0.160
- ADIPOGENESIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-21-A5DI-01A-31R-A26W-07 | — | cohortSQ1 | 0.830 |
| 2 | TCGA-85-A4CN-01A-11R-A24H-07 | — | cohortSQ2 | 0.822 |
| 3 | TCGA-63-A5MJ-01A-11R-A27Q-07 | — | cohortSQ2 | 0.816 |
| 4 | TCGA-39-5019-01A-01R-1820-07 | — | cohortSQ2 | 0.786 |
| 5 | TCGA-92-8063-01A-11R-2247-07 | — | cohortSQ1 | 0.776 |
| 6 | TCGA-85-6798-01A-11R-1949-07 | — | cohortSQ2 | 0.774 |
| 7 | SRR6013551 | — | cohortSQ1 | 0.772 |
| 8 | MNG715 | — | — | 0.772 |
| 9 | SRR8518200 | — | E | 0.768 |
| 10 | MNG618 | — | — | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |